Psychedelics

Here are highlights from the week in Psychiatric Times.

The outcomes of this study are expected to inform the development of the upcoming PATHFINDER-52 phase 2b clinical trial.

Here are highlights from the week in Psychiatric Times.

Following the vote of the US Food and Drug Administration Psychopharmacologic Drugs Advisory Committee, Lykos has released a statement on MDMA-assisted therapy.

The Psychiatric Times Editor-in-Chief discusses the clinical uses and casual prescribing of ketamine for the treatment of psychiatric disorders.

Here are highlights from the week in Psychiatric Times.

Psychiatric Times Editor-in-Chief shares his thoughts on the FDA Psychopharmacologic Drugs Advisory Committee decision for MDMA.

The FDA Psychopharmacologic Drugs Advisory Committee voted against recommending approval for psychedelic MDMA.

The FDA Meeting of the Psychopharmacologic Drugs Advisory Committee evaluating the New Drug Application for MDMA is happening now. How do clinicians feel about this potential treatment for PTSD?

A lead educator and clinical consultant in the Lykos Therapeutics MDMA Therapist Education Program discusses MDMA-assisted therapy’s potential.

Some clinicians are skeptical about the potential of MDMA-assisted therapy...

If approved, how will MDMA-assisted therapy impact clinical psychiatry? The CEO of Lykos Therapeutics shares her thoughts.

In advance of the June 4 FDA Advisory Committee Meeting on MDMA-assisted therapy, we sat down with Alejandra Alva, MD, to get his first impressions.

Answer a quick question on psychedelics!

Answer a quick question about psychedelics!

Answer a quick question on psychedelics!

How effective is this treatment in real-world clinical settings? Experts explore this in a poster presented at the 2024 ASCP Annual Meeting.

Answer a quick question on psychedelics!

Learn more about the potential of MDMA-assisted psychotherapy.

Answer a quick question on psychedelics!

Answer a quick question on psychedelics!

Learning to use a psychedelic agent can be challenging when the protocols are not defined. Here’s how a psychiatrist got started.

According to the chief medical officer of MindMed, it is time to look past the history of LSD.

Generalized anxiety disorder: has it been sidelined by MDD? MM-120 is a new treatment under investigation for this disorder, making waves.

A psychiatrist explores ketamine-assisted psychotherapy in this ongoing series.

Here are highlights from the week in Psychiatric Times.

Psychedelics: it is time to integrate this treatment option into clinical care while holding fast to the principles of medical ethics.

Study results suggest the potential for a scalable, single-dose treatment approach.

Lykos Therapeutics recently received priority review of MDMA-assisted therapy for patients with PTSD. Check out the latest research update here!

The short-acting psychedelic, BPL-003, resulted in rapid, durable depression symptom reduction in patients with TRD.